Biobehavioral Influences on Cancer Progression

Immunology and Allergy Clinics of North America

Volumn 31, Issue 1, 2011, Pages 109-132

  Costanzo, Erin S ^a   Sood, Anil K ^b   Lutgendorf, Susan K ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Angiogenesis; Cancer; Depression; Immunity; Inflammation; Stress

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

BEHAVIOR THERAPY; BREAST CANCER; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; DEPRESSION; DRUG MECHANISM; GENE CONTROL; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MACROPHAGE; MALIGNANT TRANSFORMATION; MEDITATION; METASTASIS; MUSCLE RELAXATION; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STRESS MANAGEMENT; TUMOR VASCULARIZATION; YOGA;

DEPRESSION; DISEASE PROGRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNOSUPPRESSION; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PITUITARY-ADRENAL SYSTEM; RESILIENCE, PSYCHOLOGICAL; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL; SYMPATHETIC NERVOUS SYSTEM;

EID: 78649352268     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2010.09.001     Document Type: Review

References (219)

1. Daly M., Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998, 25(3):255-264.
2. Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J Psychosom Res 1991, 35(2-3):355-363.
3. Duijts S.F.A., Zeegers M.P.A., Borne B.V. The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer 2003, 107(6):1023-1029.
4. Lillberg K., Verkasalo P.K., Kaprio J., et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol 2003, 157(5):415-423.
5. Michael Y.L., Carlson N.E., Chlebowski R.T., et al. Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol 2009, 28(2):137-146.
6. Lutgendorf S.K., Costanzo E.S., Siegel S. Psychosocial influences in oncology: an expanded model of biobehavioral mechanisms. Psychoneuroimmunology 2007, 869-896. Elsevier Academic Press, San Diego (CA). 4th edition. R. Ader (Ed.).
7. Palesh O., Butler L.D., Koopman C., et al. Stress history and breast cancer recurrence. J Psychosom Res 2007, 63(3):233-239.
8. Satin J.R., Linden W., Phillips M.J. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009, 115(22):5349-5361.
9. Steel J.L., Geller D.A., Gamblin T.C., et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007, 25(17):2397-2405.
10. Petticrew M., Bell R., Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. Br Med J 2002, 325(7372):1066-1076.
11. Stommel M., Given B.A., Given C.W. Depression and functional status as predictors of death among cancer patients. Cancer 2002, 94(10):2719-2727.
12. Epping-Jordan J., Compas B., Howell D. Predictors of cancer progression in young adult men and women: avoidance, intrusive thoughts, and psychological symptoms. Health Psychol 1994, 13(6):539-547.
13. Brown J.E., Butow P.N., Culjak G., et al. Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer 2000, 83(11):1448-1453.
14. Ell K., Nishimoto R., Mediansky L., et al. Social relations, social support, and survival among patients with cancer. J Psychosom Res 1992, 36(6):531-541.
15. Maunsell E., Brisson J., Deschenes L. Social support and survival among women with breast cancer. Cancer 1995, 76(4):631-637.
16. Waxler-Morrison N., Hislop T.G., Mears B., et al. Effects of social relationships on survival for women with breast cancer: a prospective study. Soc Sci Med 1991, 33(2):177-183.
17. Kroenke C.H., Kubzansky L.D., Schernhammer E.S., et al. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 2006, 24(7):1105-1111.
18. Chida Y., Hamer M., Wardle J., et al. Do stress-related psychosocial factors contribute to cancer incidence and survival?. Nat Clin Pract Oncol 2008, 5(8):466-475.
19. Lazarus R., Folkman S. Stress, appraisal, and coping 1984, Springer, New York.
20. Andersen B., Farrar W.B., Golden-Kreutz D., et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998, 90(1):30-36.
21. Meyerowitz B. Psychosocial correlates of breast cancer and its treatments. Psychol Bull 1980, 87(1):108-131.
22. Andersen B., Kiecolt-Glaser J., Glaser R. A biobehavioral model of cancer stress and disease course. Am Psychol 1994, 49(5):389-404.
23. Monroe S.M., Slavich G.M., Torres L.D., et al. Severe life events predict specific patterns of change in cognitive biases in major depression. Psychol Med 2007, 37(6):863-871.
24. Monroe S.M., Slavich G.M., Torres L.D., et al. Major life events and major chronic difficulties are differentially associated with history of major depressive episodes. J Abnorm Psychol 2007, 116(1):116-124.
25. Monroe S.M., Harkness K.L. Life stress, the " kindling" hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev 2005, 112(2):417-445.
26. Becker J., Kleinman A. Psychosocial aspects of depression 1991, Erlbaum, Hillsdale (NJ).
27. Massie M.J. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004, 32:57-71.
28. Spoletini I., Gianni W., Repetto L., et al. Depression and cancer: an unexplored and unresolved emergent issue in elderly patients. Crit Rev Oncol Hematol 2008, 65(2):143-155.
29. Costanzo E.S., Ryff C.D., Singer B. Psychosocial adjustment among cancer survivors: findings from a national survey of health and well-being. Health Psychol 2009, 28:147-156.
30. Cohen S., Wills T. Stress, social support, and the buffering hypothesis. Psychol Bull 1985, 98(2):310-357.
31. Social support measurement and intervention 2000, Oxford University Press, New York. S. Cohen, L.G. Underwood, B.H. Gottlieb (Eds.).
32. Cutrona C., Russell D. Type of social support and specific stress: toward a theory of optimal matching. Social support: an interactional view 1990, 319-366. Wiley, New York. B.R. Sarason, I.G. Sarason, G.R. Pierce (Eds.).
33. Cornwell E.Y., Waite L.J. Social disconnectedness, perceived isolation, and health among older adults. J Health Soc Behav 2009, 50(1):31-48.
34. House J.S., Landis K.R., Umberson D. Social relationships and health. Science 1988, 241(4865):540-545.
35. Weiner H. Perturbing the organism: the biology of stressful experience 1992, University of Chicago Press, Chicago.
36. Antoni M., Lutgendorf S., Cole S., et al. The influence of bio-behavioural factors on tumor biology: pathways and mechanisms. Nat Rev Cancer 2006, 6(3):240-248.
37. Madden K. Catcholamines, sympathetic innervation, and immunity. Brain Behav Immun 2003, 17:S5-S10.
38. Felten D.L., Felten S.Y. Innervation of lymphoid tissue. Psychoneuroimmunology 1991, 87-101. Academic Press, San Diego (CA). R. Ader, D.L. Felten, N. Cohen (Eds.).
39. Irwin M.R., Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007, 21(4):374-383.
40. Elenkov I.J., Wilder R.L., Chrousos G.P., et al. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000, 52(4):595-638.
41. Chrousos G.P. Stress and disorders of the stress system. Nat Rev Endocrinol 2009, 5(7):374-381.
42. Khan M.M., Sansoni P., Silverman E.D., et al. Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochem Pharmacol 1986, 35(7):1137-1142.
43. Hellstrand K., Hermodsson S., Strannegard O. Evidence for beta-adrenoceptor-mediated regulation of human natural killer cells. J Immunol 1985, 134(6):4095-4099.
44. Zorilla E.P., Luborsky L., McKay J.R. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001, 15(3):199-226.
45. Kiecolt-Glaser J.K., McGuire L., Robles T.F., et al. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu Rev Psychol 2002, 53:83-107.
46. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998.
47. Cerwenka A., Lanier L. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001, 1(1):41-49.
48. Reiche E.M., Nunes S.O., Morimoto H.K. Stress, depression, the immune system, and cancer. Lancet Oncol 2004, 5(10):617-625.
49. Kiecolt-Glaser J.K., Robles T.F., Heffner K.L., et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol 2002, 13(Suppl 4):165-169.
50. Heffner K.L., Loving T.J., Robles T.F., et al. Examining psychosocial factors related to cancer incidence and progression: in search of the silver lining. Brain Behav Immun 2003, 17(Suppl 1):S109-S111.
51. Saul A.N., Oberyszyn T.M., Daugherty C., et al. Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst 2005, 97(23):1760-1767.
52. Ben-Eliyahu S., Page G.G., Yimira R., et al. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999, 80(6):880-888.
53. Ben-Eliyahu S., Yirmiya R., Liebeskind J.C., et al. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun 1991, 5(2):193-205.
54. Greenfeld K., Avraham R., Benish M., et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 2007, 21(4):503-513.
55. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003, 17:27-36.
56. Ben-Eliyahu S., Shakhar G., Page G.G., et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000, 8(3):154-164.
57. Page G.G., Ben-Eliyahu S. A role for NK cells in greater susceptibility of young rats to metastatic formation. Dev Comp Immunol 1999, 23(1):87-96.
58. Levy S., Herberman R., Lippman M., et al. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 1987, 5(3):348-353.
59. Levy S.M., Heberman R.B., Maluish A.M., et al. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. Health Psychol 1985, 4(2):99-113.
60. Levy S.M., Heberman R.B., Whiteside T., et al. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med 1990, 52(1):73-85.
61. Levy S.M., Herberman R.B., Lee J., et al. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul 1990, 9(5):313-324.
62. Levy S.M., Heberman R.B., Lippman M., et al. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991, 17(2):67-75.
63. Varker K.A., Terrell C.E., Welt M., et al. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res 2007, 139(1):36-44.
64. Thornton L.M., Andersen B.L., Crespin T.R., et al. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun 2007, 21(2):185-194.
65. Garland M.R., Lavelle E., Doherty D., et al. Cortisol does not mediate the suppressive effects of psychiatric morbidity on natural killer cell activity: a cross-sectional study of patients with early breast cancer. Psychol Med 2004, 34(3):481-490.
66. Tjemsland T., Soreide J.A., Matre R., et al. Preoperative psychological variables predict immunological status in patients with operable breast cancer. Psychooncology 1997, 6(4):311-320.
67. Von Ah D., Kang D., Carpenter J. Stress, optimism, and social support: Impact on immune responses in breast cancer. Res Nurs Health 2007, 30(1):72-83.
68. McGregor B.A., Antoni M.H., Boyers A., et al. Cognitive-behavioral stress management increased benefit finding and immune function among women with early-stage breast cancer. J Psychosom Res 2004, 56(1):1-8.
69. Blomberg B.B., Alvarez J.P., Diaz A., et al. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J Psychosom Res 2009, 67(5):369-376.
70. Nan K., Wei Y., Zhou F.L., et al. Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers. World J Gastroenterol 2004, 10(2):268-272.
71. Dunigan J.T., Carr B.I., Steel J.L. Posttraumatic growth, immunity and survival in patients with hepatoma. Dig Dis Sci 2007, 52(9):2452-2459.
72. Penedo F.J., Dahn J.R., Kinsinger D., et al. Anger suppression mediates the relationship between optimism and natural killer cell cytotoxicity in men treated for localized prostate cancer. J Psychosom Res 2006, 60(4):423-427.
73. Zhou F.L., Zhang W.G., Wei Y.C., et al. Impact of comorbid anxiety and depression on quality of life and cellular immunity changes in patients with digestive tract cancers. World J Gastroenterol 2005, 11(15):2313-2318.
74. Lutgendorf S.K., Sood A.K., Andersen B., et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 2005, 23(28):7105-7113.
75. Yermal S.J., Witek-Janusek L., Peterson J., et al. Perioperative pain, psychological distress, and immune function in men undergoing prostatectomy for cancer of the prostate. Biol Res Nurs 2009, 11:351-362.
76. Lamkin D.M., Lutgendorf S.K., McGinn S., et al. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun 2008, 22(1):65-73.
77. Lutgendorf S.K., Lamkin D.M., DeGeest K., et al. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun 2008, 22(6):890-900.
78. Fidler I.J. Critical factors in the biology of human cancer metastasis. Am Surg 1995, 61(12):1065-1066.
79. Fidler I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995, 87(21):1588-1592.
80. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42(6):745-750.
81. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
82. Skobe M., Fusenig N.E. Tumorigenic conversion of immortal human keratinocytres through stromal cell activation. Proc Natl Acad Sci U S A 1998, 95(3):1050-1055.
83. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
84. Folkman J. Tumor angiogenesis. The molecular basis of cancer 1995, WB Saunders, Philadelphia, p. 206-32.
85. Folkman J. What is the evidence that tumors are angiogenesis dependant?. J Natl Cancer Inst 1990, 82:4-6.
86. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235(4787):442-447.
87. Fidler I.J. Molecular biology of cancer: invasion and metastasis. Cancer: principles and practice of oncology 1997, 135-152. JB Lippincott, Philadelphia. 5th edition. V.T. DeVita, S. Hellman, S. Rosenberg (Eds.).
88. Sood A.K., Coffin J.E., Schneider G.B., et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004, 165(4):1087-1095.
89. Sood A.K., Bhatty R., Kamat A.A., et al. Stress hormone mediated invasion of ovarian cancer cells. Clin Cancer Res 2006, 12(2):369-375.
90. Sood A., Lutgendorf S., Cole S. Neuroendocrine regulation of cancer progression: I. Biological mechanisms and clinical relevance. Psychoneuroimmunology 2007, vol. IV:233-250. Elsevier, San Diego (CA). R. Ader, N. Cohen, D. Felten (Eds.).
91. Thaker P., Han L.Y., Kamat A.A., et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006, 12(8):939-944.
92. Sood A.K., Armaiz-Pena G., Halder J., et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010, 120(5):1515-1523.
93. Yang E.V., Kim S.J., Donovan E.L., et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009, 23(2):267-275.
94. Yang E.V., Sood A.K., Chen M., et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006, 66(21):10357-10364.
95. Nilsson M.B., Armaiz-Pena G., Takahashi R., et al. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. J Biol Chem 2007, 282(41):29919-29926.
96. Lutgendorf S.K., Lamkin D.M., Jennings N.B., et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008, 14(21):6839-6846.
97. Lutgendorf S.K., Cole S., Costanzo E., et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003, 9(12):4514-4521.
98. Lee J., Shahzad M.M., Lin Y.G., et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009, 15(8):2695-2702.
99. Lutgendorf S.K., Johnsen E.L., Cooper B., et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002, 95(4):808-815.
100. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65(23):10794-10800.
101. Cohen T., Nahari D., Cerem L.W., et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271(2):736-741.
102. Eustace D., Han X., Gooding R., et al. Interleukin 6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993, 50(1):15-19.
103. Obata N.H., Tamakoshi K., Shibata K., et al. Effects of interleukin-6 on in vitro cell attachment, migration, and invasion of human ovarian carcinoma. Anticancer Res 1997, 17(1A):337-342.
104. Kitamura Y., Morita I., Nihel Z., et al. Effects of IL-6 on tumor cells invasion of vascular endothelial monolayers. Jpn J Surg 1997, 27:534-541.
105. Berek J.S., Chung C., Kaldi K., et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164(4):1038-1043.
106. Chopra V., Dinh T.V., Hannigan E. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998, 16(3):152-159.
107. Scambia G., Testa U., Benedetti P., et al. Prognostic significance of IL-6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71(2):352-356.
108. Mastorakos G., Chrousos G.P., Weber J.S. Recombinant interleukin-6 activates the hypothalamic pituitary adrenal axis in humans. J Clin Endocrinol Metab 1993, 77(6):1690-1694.
109. Zhou D., Kusnecov A., Shurin M., et al. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993, 133(6):2523-2530.
110. Spangelo B.L., MacLeod R.M., Isakson P.C. Production of interleukin-6 by anterior pituitary cells in vitro. Endocrinology 1990, 126(1):582-586.
111. Papanicolaou D., Petrides J., Tsigos C., et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996, 271(3 PT 1):e601-e605.
112. DeRijk R., Sternberg E. Corticosteroid action and neuroendocrine-immune interactions. Ann N Y Acad Sci 1994, 746:33-41.
113. Frommberger U.H., Bauer J., Haselbauer P., et al. Interleukin-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247(4):228-233.
114. Lutgendorf S., Garand L., Buckwalter K., et al. Life stress, mood disturbance, and elevated IL-6 in healthy older women. J Gerontol A Biol Sci Med Sci 1999, 54(9):M434-M439.
115. Maes M., Bosmans E., de Jongh R., et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9(11):853-858.
116. Krause A., Holtmann H., Eickemeier S., et al. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1 induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem 1998, 273(37):23681-23689.
117. Costanzo E.S., Lutgendorf S.K., Sood A.K., et al. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005, 104(2):305-313.
118. Suzuki K., Yamada M., Kurakake S., et al. Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. Eur J Appl Physiol 2000, 81(4):281-287.
119. Tayama E., Hayashida M., Oda T., et al. Recovery from lymphocytopenia following extracorporeal circulation: simple indicator to assess surgical stress. Artif Organs 1999, 23(8):736-740.
120. Landen C.N., Lin Y.G., Armaiz-Pena G.N., et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007, 67(21):10389-10396.
121. Masur K., Niggemann B., Zanker K.S., et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001, 61(7):2866-2869.
122. Drell T.L., Joseph J., Lang K., et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003, 80:63-70.
123. Yang E., Bane C.M., MacCallum R.C., et al. Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol 2002, 133(1-2):144-150.
124. Lutgendorf S.K., Weinrib A.Z., Penedo F., et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008, 26(29):4820-4827.
125. Lutgendorf S.K., DeGeest K., Sung C.Y., et al. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 2009, 23(2):176-183.
126. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
127. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78.
128. Sica A., Schioppa T., Mantovani A., et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour. Eur J Cancer 2006, 42(6):717-727.
129. Huang S., Van Arsdall M., Tedjarati S., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002, 94(15):1134-1142.
130. Hagemann T., Robinson S.C., Schulz M., et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25(8):1543-1549.
131. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267(2):204-215.
132. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-265.
133. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7(3):211-217.
134. Tsutsui S., Yasuda K., Suzuki K., et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005, 14(2):425-431.
135. Miller G.E., Cohen S., Ritchey A.K. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol 2002, 21(6):531-541.
136. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002, 16(6):622-653.
137. Szelenyi J., Kiss J.P., Puskas E., et al. Contribution of differently localized alpha 2- and beta-adrenoceptors in the modulation of TNF-alpha and IL-10 production in endotoxemic mice. Ann N Y Acad Sci 2000, 917:145-153.
138. Van Miert A. Present concepts on the inflammatory modulators with special reference to cytokines. Vet Res Commun 2002, 26(2):111-126.
139. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002, 966:290-303.
140. Cole S.W., Hawkley L.C., Arevalo J.M., et al. Social regulation of gene expression in human leukocytes. Genome Biol 2007, 8(9):R189.
141. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160(9):1554-1565.
142. Maier S., Watkins L. Cytokines for psychologists: implications of bidirectional immune to brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998, 105(1):83-107.
143. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27(1):24-31.
144. Capuron L., Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17:S119-S124.
145. Miller G.E., Chen E., Sze J., et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol Psychiatry 2008, 64(4):266-272.
146. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003, 54(3):269-282.
147. Musselman D.L., Miller A.H., Porter M.R., et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001, 158(8):1252-1257.
148. Jehn C.F., Kuehnhardt D., Bartholomae A., et al. Biomarkers of depression in cancer patients. Cancer 2006, 107(11):2723-2729.
149. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005, 11(5):1757-1764.
150. Weinrib A., Sephton S.E., DeGeest K., et al. Diurnal cortisol dysregulation: links with depression and functional disability in women with ovarian cancer. Cancer 2010, 116(18):4410-4419.
151. Bower J.E., Ganz P.A., Aziz N., et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002, 64(4):604-611.
152. Collado-Hidalgo A., Bower M.E., Ganz P.A., et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006, 12(9):2759-2766.
153. Bower J.E., Ganz P.A., Dickerson S.S., et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005, 30(1):92-100.
154. Collado-Hidalgo A., Bower J.E., Ganz P.A., et al. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. J Brain Behav Immun 2008, 22(8):1197-1200.
155. Jacobsen P.B., Jim H.S. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin 2008, 58(4):214-230.
156. Uitterhoeve R.J., Vernooy M., Litjens M., et al. Psychosocial interventions for patients with advanced cancer - a systematic review of the literature. Br J Cancer 2004, 91(6):1050-1062.
157. Daniels J., Kissane D.W. Psychosocial interventions for cancer patients. Curr Opin Oncol 2008, 20(4):367-371.
158. Antoni M.H., Lechner S.C., Kazi A., et al. How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 2006, 74(6):1143-1152.
159. Spiegel D., Bloom G., Kramer J., et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989, 2(8668):888-891.
160. Fawzy F.I., Fawzy N.W., Hyun C.S., et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50(9):681-689.
161. Fox B.A. A hypothesis about Spiegel et al.'s 1989 paper on psychosocial intervention and breast cancer survival. Psychooncology 1998, 7(5):361-370.
162. Kogon M.M., Biswas A., Pearl D., et al. Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer 1997, 80(2):225-230.
163. Coyne J., Stefanek M., Palmer S. Psychotherapy and survival in cancer: the conflict between hope and evidence. Psychol Bull 2007, 133(3):367-394.
164. Cunningham L.L., Andrykowski M.A., Wilson J.F., et al. Physical symptoms, distress, and breast cancer risk perceptions in women with benign breast problems. Health Psychol 1998, 17(4):371-375.
165. Edelman S., Bell D.R., Kidman A.D. A group cognitive behavioral therapy programme with metastatic breast cancer patients. Psychooncology 1999, 8(4):295-305.
166. Edelman S., Lemon J., Bell D.R., et al. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 1999, 8(6):474-481.
167. Goodwin P., Leszcz M., Ennis M., et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001, 345(24):1719-1726.
168. Kissane D.W., Grabsch B., Clarke D.M., et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007, 16(4):277-286.
169. Spiegel D., Butler L.D., Giese-Davis J., et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 2007, 110(5):1130-1137.
170. Ilnyckyj A., Farber J., Cheang M., et al. A randomized controlled trial of psychotherapeutic intervention in cancer patients. Ann R Coll Physicians Surg Can 1994, 27:93-96.
171. Gellert G.A., Maxwell R.M., Siegel B.S. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993, 11(1):66-69.
172. Kissane D.W., Love A., Hatton H., et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 2004, 22(21):4255-4260.
173. Andersen B.L., Yang H.C., Farrar W.B., et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008, 113(12):3450-3458.
174. Kuchler T., Bestmann B., Rappat S., et al. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol 2007, 25(19):2702-2708.
175. Kuchler T., Henne-Bruns D., Rappat S., et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology 1999, 46(25):322-335.
176. Fawzy F.I., Canada A.L., Fawzy N.W. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1):100-103.
177. Phillips K.M., Antoni M.H., Lechner S.C., et al. Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med 2008, 70(9):1044-1049.
178. Antoni M.H., Wimberly S.R., Lechner S.C., et al. Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry 2006, 163(10):1791-1797.
179. Antoni M.H., Lechner S., Diaz A., et al. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 2009, 23(5):580-591.
180. Andersen B.L., Farrar W.B., Golden-Kreutz D.M., et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004, 22(17):3570-3580.
181. Andersen B.L., Farrar W.B., Golden-Kreutz D., et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 2007, 21(7):953-961.
182. Thornton L.M., Andersen B.L., Schuler T.A., et al. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med 2009, 71(7):715-724.
183. Carlson L.E., Garland S.N. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. Int J Behav Med 2005, 12(4):278-285.
184. Carlson L.E., Speca M., Faris P., et al. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun 2007, 21(8):1038-1049.
185. Carlson L.E., Speca M., Patel K.D., et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 2003, 65(4):571-581.
186. Witek-Janusek L., Albuquerque K., Chroniak K.R., et al. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun 2008, 22(6):969-981.
187. Eremin O., Walker M.B., Simpson E., et al. Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomized controlled trial. Breast 2009, 18(1):17-25.
188. Gruber B.L., Hersh S.P., Hall N.R.S., et al. Immunological responses of breast cancer patients to behavioral interventions. Biofeedback Self Regul 1993, 18(1):1-22.
189. Lengacher C.A., Bennett M.P., Gonzalez L., et al. Immune responses to guided imagery during breast cancer treatment. Biol Res Nurs 2008, 9(3):205-214.
190. Bakke A.C., Purtzer M.Z., Newton P. The effect of hypnotic-guided imagery on psychological well-being and immune function in patients with prior breast cancer. J Psychosom Res 2002, 53(6):1131-1137.
191. Schedlowski M., Jung C., Schimanski G., et al. Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: an exploratory study. Psychooncology 1994, 3:181-187.
192. Savard J., Simard S., Giguere I., et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care 2006, 4(3):219-237.
193. Ross L., Frederiksen K., Boesen S.H., et al. No effect on survival of home psychosocial intervention in a randomized study of Danish colorectal cancer patients. Psychooncology 2009, 18(8):875-885.
194. Hosaka T., Tokuda Y., Sugiyama Y., et al. Effects of a structured psychiatric intervention on immune function of cancer patients. Tokai J Exp Clin Med 2000, 25(4-6):183-188.
195. Savard J., Simard S., Ivers H., et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part II: immunologic effects. J Clin Oncol 2005, 23(25):6097-6106.
196. Eismann E.A., Lush E., Sephton S.E. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. Psychoneuroendocrinology 2010, 35(7):963-976.
197. Sephton S., Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?. Brain Behav Immun 2003, 17(5):321-328.
198. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26(5):643-652.
199. Morrow G.R., Hickok J.T., Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003, 21(24):4635-4641.
200. Kubera M., Grygier B., Arteta B., et al. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep 2009, 61:1113-1126.
201. Lee C.S., Kim Y.J., Jang E.R., et al. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kB. Basic Clin Pharmacol Toxicol 2010, 106(6):446-453.
202. Melemed A.S., Mockbee C., Orlando M. Comprehensive review of chemotherapy in patients with metastatic breast cancer. J Clin Oncol 2005, 23(31):8139-8140.
203. Ben-Eliyahu S., Page G.G., Schleifer S.J. Stress, NK cells, and cancer: still a promissory note. Brain Behav Immun 2007, 21(7):881-887.
204. Perron L., Bairati I., Harel F., et al. Antihypertensive drug use and the risk of prostate cancer. Cancer Causes Control 2004, 15:535-541.
205. Avraham R., Benish M., Inbar S., et al. Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav Immun 2010, 24(6):952-958.
206. Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Clin Oncol 2003, 10(8):972-992.
207. Uchida A., Kariya Y., Okamoto N., et al. Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 1990, 82(21):1697-1701.
208. Mccoy J.L., Rucker R., Petros J.A. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat 2000, 60(3):227-234.
209. Bacigalupo A. Results of allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Hematology: basic principles and practice 2005, 1713-1726. Churchill Livingstone, Philadelphia. 4th edition. R. Hoffman (Ed.).
210. Schriber J.R., Forman S.J. Autologous transplantation for hematologic malignancies and solid tumors. Hematology: basic principles and practice 2005, 1727-1738. Churchill Livingstone, Philadelphia. 4th edition. R. Hoffman (Ed.).
211. Porrata L.F., Litzow M., Markovic S.N. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001, 76(4):407-412.
212. Neitzert C.S., Ritvo P., Dancey J., et al. The psychosocial impact of bone marrow transplantation: a review of the literature. Bone Marrow Transplant 1998, 22(5):409-422.
213. Colon E.A., Callies A.L., Popkin M.K., et al. Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics 1991, 32(4):420-425.
214. Molassiotis A., Van den Akker O.B.A., Milligan D.W., et al. Symptom distress, coping style and biological variables as predictors of survival after bone marrow transplantation. J Psychosom Res 1997, 42(3):275-285.
215. Hoodin F., Kalbfleisch K.R., Thornton J., et al. Psychosocial influences on 305 adults' survival after bone marrow transplantation; depression, smoking, and behavioral self-regulation. J Psychosom Res 2004, 57(2):145-154.
216. Rodrigue J.R., Pearman T.P., Moreb J. Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. Int J Behav Med 1999, 6(3):241-254.
217. Porrata L.F., Markovic S.N. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004, 4(2):78-85.
218. Peggs K.S., Mackinnon S. Immune reconstitution following haematopoietic stem cell transplantation. Br J Haematol 2004, 124(4):407-420.
219. Auletta J.J., Lazarus H.M. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005, 35(9):835-837.